Clinical studies 2022

Pleuran (oyster β-glucan) for preventing recurrent respiratory infections in children: an international n=1030 study

The largest observational study of pleuran (oyster β-glucan) in children with recurrent respiratory infections: over 3 months of supplementation + 3 months follow-up, RTI episodes fell from 7.07 to 3.87. But it is before/after with no placebo — we flag the design honestly.

Dvorak B.F. et al. Beta-(1,3/1,6)-D-glucan from Pleurotus ostreatus in the prevention of recurrent respiratory tract infections: An international multicentric clinical study. Front Pediatr. 2022;10:1009878.

Why this study

Oyster β-glucans are among the most-studied "immune" components of mushrooms. Pleuran (β-(1,3/1,6)-glucan) is sold as a supplement for children with frequent colds. This is the first large international study on a real population.

Methods

  • 1030 children (mean age 3.5) from 7 countries with recurrent RTIs.
  • 3 months of pleuran + 3 months of follow-up; comparison with the same period of the previous year (October–March).
  • Endpoints: number and duration of RTIs by type (upper/lower).

Findings

  • RTI count fell from 7.07 to 3.87 episodes per half-year (−45%, p<0.001).
  • Reductions across all RTI subtypes, including duration.
  • Safety profile confirmed — no serious AEs recorded.

Limitations — important

  • Before/after design with no placebo or randomization: comparing with one's own previous year is sensitive to seasonality (mild/severe epidemic year), the child's maturing immunity and the "being observed" effect.
  • Manufacturer-sponsored work — take into account.

Why it matters

Pleuran is a rare mushroom product with paediatric data and a large sample. But the card is a teaching example that "large n ≠ randomized design": the effect may be real (it fits β-glucan mechanism), but the evidential strength is below an RCT.